Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of radiotherapy with durvalumab and tremelimumab in advanced or metastatic NSCLC after progression on first-line immunotherapy
MOH_2022-07-13_011905Phase 2Recruiting
- Sponsor
- פרופ' יאיר בר
- Start
- Dec 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in non-small cell lung cancer (NSCLC), sponsored by פרופ' יאיר בר. Primary endpoints: Safety of radiotherapy combined with durvalumab and tremelimumab, Objective response rate and 1 more. Started Dec 2020; status: recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2022-07-13_011905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-13_011905.